Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.
mTOR inhibitors avoid calcineurin nephrotoxicity, but sirolimus de novo is associated with unacceptable side effects and higher rejection rates. We have investigated a modified strategy: alemtuzumab induction with tacrolimus and mycophenolate maintenance, switching from tacrolimus to sirolimus at 6...
Huvudupphovsmän: | Sutherland, A, Akhtar, M, Zilvetti, M, Brockmann, J, Ruse, S, Fuggle, S, Sinha, S, Harden, P, Friend, P |
---|---|
Materialtyp: | Conference item |
Publicerad: |
2014
|
Liknande verk
Liknande verk
-
Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.
av: Flechner, S, et al.
Publicerad: (2005) -
Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
av: Trzonkowski, P, et al.
Publicerad: (2008) -
ALEMTUZUMAB INDUCTION IN PANCREAS TRANSPLANTATION
av: Muthusamy, A, et al.
Publicerad: (2011) -
Systematic reviews of alemtuzumab in renal transplantation.
av: O'Callaghan, J, et al.
Publicerad: (2013) -
Systematic reviews of alemtuzumab in renal transplantation
av: O'Callaghan, J, et al.
Publicerad: (2013)